11:-03-08

tw

OCT 3 1 2008

Typed or printed name

PTO/SB/21 (10-07) Approved for use through 10/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 08/208,972 (U.S. Pat.#5,451,233) TRANSMITTAL Filing Date 03/09/1994 First Named Inventor **FORM** Paul G. Yock Art Unit N/A **Examiner Name** N/A (to be used for all correspondence after initial filing) Attorney Docket Number 077843.0113 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC 1 Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify **Terminal Disclaimer** Extension of Time Request below): Disclosure Submission Pursuant to 37 CFR Request for Refund Express Abandonment Request 1.765 (2 pages) with Appendices A-C CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Original and two copies submitted. Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Baker Botts L.L.P. Signature Printed name Jason C. Chumney Date Reg. No. 10/31/2008 54.781 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EEE TOANGAITTAI	Complete if Known		
FEE TRANSMITTAL	Application Number	08/208,972 (U.S. Pat.#5,451,233)	
for FY 2007	Filing Date	03/09/1994	
101112001	First Named Inventor	Paul G. Yock	
☐ . I'	Examiner Name	N/A	
Applicant claims small entity status. See 37 CFR 1.27	Art Unit	N(A	
TOTAL AMOUNT OF PAYMENT (\$) 0	Attorney Docket No.	077843.0113	
METHOD OF PAYMENT (check all that apply)	FEE CA	LCULATION (continued)	
Check Credit card Money Other None ADDITIONAL FEES			
✓ Deposit Account:			
Deposit Account 02-4377	٦		
Number Deposit Account Baker Botts L.L.P.	」Surcharge - late oa	ith or filing fee	
Name	Non-English Specif	fication	
The Director is authorized to: (check all that apply)  Charge fee(s) indicated below  Credit any overpayments	Extension for reply	within first month	
Charge any additional fee(s) or any underpayment of fee(s)  Charge fee(s) indicated below, except for the filing fee	Extension for reply	within second month	
to the above-identified deposit account.	Extension for reply	within third month	
FEE CALCULATION  Extra Claim Fees	Extension for reply	within fourth month	
Extra Ciallii Fees	Extension for reply	within fifth month	
Extra Claims Fee Fee Paid	Notice of Appeal		
Total Claims x 52 = \$0	Filing a brief in sup	port of an appeal	
Independent Claims x 220 = \$0	Petition to revive -	unavoidable	
Multiple Dependent = \$0	Petition to revive -	unintentional	
	Utility Issue Fee		
SUBTOTAL \$0	Design Issue Fee		
	Publication Fee		
Fee Description Large Entity Small Entity	Petitions to the Cor	mmissioner	
Claims in excess of 20 52 26	Request for Contin	ued Examination (RCE)	
Independent claims in excess of 3	Information Disclos	sure Statement (IDS)	
Multiple dependent claim, if not paid 195 Ot	her fee - Disclosure Submissi Appendices A-C	ion Pursuant to 37 CFR Section 1.765 with	
SUBTOTAL (\$) 0			
SUBMITTED BY (Complete (if applicable))			
Name (Print/Type) Jason G. Chumney	Registration No. (Attorney/Agent) 54,78		
Signature Otto Vu	(Attorney/Agent) 54,70	Date 10/31/2008	
I I WWW //WWW		10/01/2000	

WARNING: Information on this form may become public. Credit card information should not be included on this form Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



plication No. (if known): 08/208,9723

# Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No ED 762055927 US in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	October 31, 2008
	Date

Arlou (Lu	$\omega$	
Signat Jason Ch	( )	
Typed or printed name of person signing Certificate		
54,781	212-408-2500	
Registration Number, if applicable	Telephone Number	

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

- DISCLOSURE STATEMENT PURSUANT TO 37 CFR § 1.765 (2 pages) with Appendices A-C and attachments (with 2 additional copies)
- 2. Transmittal Form (1 page)
- 3. Fee Transmittal Form (1 page)
- 4. Return Receipt Postcard



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

: U.S. Patent No. 5,451,233 (U.S.S.N. 08/208,972)

Issued:

September 19, 1995

Regulatory Approval Product:

XIENCE<sup>™</sup> V EECSS

Inventors

:

Paul G. Yock

For

Angioplasty Apparatus Facilitating Rapid Exchanges

## **DISCLOSURE SUBMISSION PURSUANT TO 37 CFR § 1.765**

## SUBMITTED VIA EXPRESS MAIL

Mail Stop: Hatch-Waxman PTE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Further to the Disclosure Submission filed with the United States Patent and Trademark Office ("USPTO") on September 22, 2008, Applicant formally submits herewith information and materials that may be relevant to a determination of entitlement to the extension sought pursuant to 35 U.S.C. § 156 for U.S. Patent No. 5,451,233 ("the '233 Patent"). Although not necessarily material or adverse to any such determination, the following information and materials is provided for consideration pursuant to 37 C.F.R. § 1.765.

Appendix A: Order issued on October 21, 2008 in connection with Medtronic, Inc.'s Motion to Modify Injunction in Advanced Cardiovascular Systems, Inc. v. Medtronic, Inc. (C.A. No. 95-03577);

Appendix B: Supplement to the Citizen Petition submitted on August 22, 2008 in connection with FDA Docket No. FDA-2008-P-0473, as filed on behalf of AngioScore, Inc.

Attorney Docket No. 077843.0113

and dated October 24, 2008 (without Exhibit A thereof, which is included

herewith as Appendix A); and

Appendix C: Comments of Abbott Cardiovascular Systems to the Citizen Petition in connection

with FDA Docket No. FDA-2008-P-0473, dated October 28, 2008 (without

Exhibit C thereof, which is included herewith as Appendix A).

Additionally, it is noted that submissions made in connection with FDA Docket No.

FDA-2008-P-0473 are available at http://www.regulations.gov/search/index.jsp.

Applicant believes the '233 Patent is eligible for an extension pursuant to 35 U.S.C. §156

based upon FDA approval of the XIENCE<sup>™</sup> V EECSS. Applicant respectfully submits that the

materials submitted herewith do not adversely impact the eligibility of the '233 Patent for such

an extension. The USPTO and/or FDA are invited to contact the undersigned with any questions

or requests for additional information regarding this matter.

Applicant authorizes the Commissioner to charge any fees and/or credit any

overpayments associated with this submission to Baker Botts L.L.P. Deposit Account No. 02-

4377, Ref. No. 077843.0113.

Date: October 31, 2008

Respectfully submitted,

Daniel J. Hulseberg

Patent Office Reg. No. 36,554

Attorneys for Applicant

Customer No. 62,614

BAKER BOTTS L.L.P.

30 Rockefeller Plaza

New York, NY 10112-4498

(212) 408-2500



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

U.S. Patent No. 5,451,233 (U.S.S.N. 08/208,972)

Issued:

September 19, 1995

Regulatory Approval Product:

XIENCE<sup>™</sup> V EECSS

Inventors

Paul G. Yock

For

Angioplasty Apparatus Facilitating Rapid Exchanges

## **DISCLOSURE SUBMISSION PURSUANT TO 37 CFR § 1.765**

## SUBMITTED VIA EXPRESS MAIL

Mail Stop: Hatch-Waxman PTE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Further to the Disclosure Submission filed with the United States Patent and Trademark Office ("USPTO") on September 22, 2008, Applicant formally submits herewith information and materials that may be relevant to a determination of entitlement to the extension sought pursuant to 35 U.S.C. § 156 for U.S. Patent No. 5,451,233 ("the '233 Patent"). Although not necessarily material or adverse to any such determination, the following information and materials is provided for consideration pursuant to 37 C.F.R. § 1.765.

Appendix A: Order issued on October 21, 2008 in connection with Medtronic, Inc.'s Motion to Modify Injunction in Advanced Cardiovascular Systems, Inc. v. Medtronic, Inc. (C.A. No. 95-03577);

Appendix B: Supplement to the Citizen Petition submitted on August 22, 2008 in connection with FDA Docket No. FDA-2008-P-0473, as filed on behalf of AngioScore, Inc.

and dated October 24, 2008 (without Exhibit A thereof, which is included herewith as Appendix A); and

Appendix C: Comments of Abbott Cardiovascular Systems to the Citizen Petition in connection with FDA Docket No. FDA-2008-P-0473, dated October 28, 2008 (without Exhibit C thereof, which is included herewith as Appendix A).

Additionally, it is noted that submissions made in connection with FDA Docket No. FDA-2008-P-0473 are available at http://www.regulations.gov/search/index.jsp.

Applicant believes the '233 Patent is eligible for an extension pursuant to 35 U.S.C. §156 based upon FDA approval of the XIENCE<sup>™</sup> V EECSS. Applicant respectfully submits that the materials submitted herewith do not adversely impact the eligibility of the '233 Patent for such an extension. The USPTO and/or FDA are invited to contact the undersigned with any questions or requests for additional information regarding this matter.

Applicant authorizes the Commissioner to charge any fees and/or credit any overpayments associated with this submission to Baker Botts L.L.P. Deposit Account No. 02-4377, Ref. No. 077843.0113.

Date: October 31, 2008

Respectfully submitted,

Daniel J. Hulseberg

Patent Office Reg. No. 36,554

Attorneys for Applicant

Customer No. 62,614

BAKER BOTTS L.L.P. 30 Rockefeller Plaza

New York, NY 10112-4498

(212) 408-2500



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

U.S. Patent No. 5,451,233 (U.S.S.N. 08/208,972)

Issued:

September 19, 1995

Regulatory Approval Product:

XIENCE<sup>™</sup> V EECSS

Inventors

Paul G. Yock

For

Angioplasty Apparatus Facilitating Rapid Exchanges

## DISCLOSURE SUBMISSION PURSUANT TO 37 CFR § 1.765

## SUBMITTED VIA EXPRESS MAIL

Mail Stop: Hatch-Waxman PTE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Further to the Disclosure Submission filed with the United States Patent and Trademark Office ("USPTO") on September 22, 2008, Applicant formally submits herewith information and materials that may be relevant to a determination of entitlement to the extension sought pursuant to 35 U.S.C. § 156 for U.S. Patent No. 5,451,233 ("the '233 Patent"). Although not necessarily material or adverse to any such determination, the following information and materials is provided for consideration pursuant to 37 C.F.R. § 1.765.

Appendix A: Order issued on October 21, 2008 in connection with Medtronic, Inc.'s Motion to Modify Injunction in Advanced Cardiovascular Systems, Inc. v. Medtronic, Inc. (C.A. No. 95-03577);

Appendix B: Supplement to the Citizen Petition submitted on August 22, 2008 in connection with FDA Docket No. FDA-2008-P-0473, as filed on behalf of AngioScore, Inc.

and dated October 24, 2008 (without Exhibit A thereof, which is included herewith as Appendix A); and

Appendix C: Comments of Abbott Cardiovascular Systems to the Citizen Petition in connection with FDA Docket No. FDA-2008-P-0473, dated October 28, 2008 (without Exhibit C thereof, which is included herewith as Appendix A).

Additionally, it is noted that submissions made in connection with FDA Docket No. FDA-2008-P-0473 are available at http://www.regulations.gov/search/index.jsp.

Applicant believes the '233 Patent is eligible for an extension pursuant to 35 U.S.C. §156 based upon FDA approval of the XIENCE<sup>™</sup> V EECSS. Applicant respectfully submits that the materials submitted herewith do not adversely impact the eligibility of the '233 Patent for such an extension. The USPTO and/or FDA are invited to contact the undersigned with any questions or requests for additional information regarding this matter.

Applicant authorizes the Commissioner to charge any fees and/or credit any overpayments associated with this submission to Baker Botts L.L.P. Deposit Account No. 02-4377, Ref. No. 077843.0113.

Date: October 31, 2008

Respectfully submitted,

Daniel J. Hulseberg

Patent Office Reg. No. 36,554

Attorneys for Applicant

Customer No. 62,614

BAKER BOTTS L.L.P.

30 Rockefeller Plaza

New York, NY 10112-4498

(212) 408-2500